Aptinyx Reports the Completion of Patient Enrollment of NYX-458 in P-II Study for Cognitive Impairment
Shots:
- The company completed the patient enrolment in the P-II study to evaluate the safety & cognitive benefits of NYX-458 (30mg) vs PBO in 99 patients with cognitive impairment associated with Parkinson’s disease & dementia with Lewy bodies. Enrolled patients have completed 12wk. treatment period & 30-day safety follow-up period
- The study evaluates the overall safety & tolerability of NYX-458 along with the effects across multiple neurocognitive EPs focused on attention, memory & executive function. The results from the P-II study are expected in Q1’23
- NYX-458 showed positive safety & tolerability profile in a P-I study while CNS exposures were consistent with exposures at efficacious preclinical dose levels
Ref: Businesswire | Image: Aptinyx
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
